Circulating Tumor DNA Guided Adjuvant Chemotherapy for Colon Cancer

The IDEA study classified stage III colon cancer into low-risk (T1-3/N1) and high-risk patients (T4 or N2) according to TNM stage. The results showed that for some low-risk patients, chemotherapy could be reduced without survival loss. In recent years, circulating tumor DNA had achieved encouraging results in monitoring recurrence and metastasis after surgery, and has potential clinical application value. Postoperative ctDNA is also considered as a marker of increased risk of recurrence for stage I-III colon cancer and can provide predictive information for decision making on adjuvant treatme

Trial Details

NCT ID
NCT05529615
Phase
NA
Sponsor
Peking University Cancer Hospital & Institute
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • detection of ctDNA
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

  • Age: 18 to 75
  • Colon adenocarcinoma confirmed by pathology (including high and high differentiated tubular adenocarcinoma, papillary adenocarcinoma, low different…
  • Postoperative pathology is stage II with high-risk factors or stage III;
  • High risk stage II refers to stage II colon cancer with at least one of the following:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →